From 10 April, we are removing .gsi from our email addresses.
Medicines And Healthcare Products Regulatory Agency
- Research: Tobacco and Vapes Bill: RPC opinion (green-rated) November 2024
- Transparency data: Business and Property Courts Rolls Building Cause List
- Press release: UKEF backs first Airbus A350-1000 delivery to African carrier
- Decision: Stamford Park Primary School: 1 November 2024
- Correspondence: Victims and Prisoners Act 2024: Implementation of the duty to collaborate
- MedSafetyWeek 2024: Preventing side effects
- What are the changes to agricultural property relief?
- Transparency data: Upper Tribunal Administrative Appeals Chamber cause list
- Guidance: First-tier Tribunal (Social Security and Child Support) hearing lists
- Transparency data: Upper Tribunal Tax and Chancery Chamber hearing list
Paying for medicines licences, clinical trials and clinical investigations is changing from 1 April the Medicines and Healthcare products Regulatory Agency (MHRA) announced.
The Medicines and Healthcare products Regulatory Agency has launched its latest guide of UK pharmaceutical regulations, EU directives and guidance.
MHRA has launched an official blog providing expert insight into the latest regulatory thinking and all aspects of medicines regulation.
MHRA has launched a ‘Week of Action’ to improve awareness of unlicensed medicines containing the potentially dangerous ingredient DMAA.
The quality of biological medicines is assured by biological standards held by the British Pharmacopoeia (BP) and the National Institute for Biological Standards and Control (NIBSC)
In a New Year with new beginnings, the dangers of fake and unlicensed medical products remain the same. We continue our campaign against fake and unlicensed medical products in 2017.
Looking back at what the Medicines and Healthcare products Regulatory Agency has achieved over the last year.
MHRA are revealing a different fact about the issue of fake and unlicensed medical products every day in December leading up to Christmas.
The Medicines and Healthcare products Regulatory Agency (MHRA) has officially launched the Joint Action on Market Surveillance of Medical Devices.
Following extensive changes to the formulation and manufacture of levothyroxine tablets by Teva, the Commission on Human Medicines (CHM) is now reassured that Teva has demonstrated an acceptable level of efficacy and safety to allow their levothyroxine tablets to re-enter the market. Additional tablet strengths have also been introduced, to improve precision of dosing.
The Medicines and Healthcare products Regulatory Agency has reviewed the classification of products containing CBD and found them to meet the definition of a medicinal product.
Statement from Medicines and Healthcare products Regulatory Agency on the risks and benefits of statins.
MHRA are experiencing technical difficulties with the customer service hotline.
If you have not yet booked your place in September's conference, book now to avoid disappointment.
Eight tips for buying medicines and medical devices online safely
A review into the sports supplement industry ahead of the Rio 2016 Olympic games shows the sport supplement industry is improving.
A review into the sports supplement industry ahead of the Rio 2016 Olympic games shows the sport supplement industry is improving.
The Medicines and Healthcare products Regulatory Agency invites interested parties to provide feedback on Clinical Trial Regulation guidance documents.
MHRA has produced draft GxP data integrity guidance for industry and we welcome your comments
Web-RADR: Recognising Adverse Drug Reactions is running a survey for healthcare providers, patients, and consumers of medicines to help develop the next generation of online side-effect reporting software.
The Agency's response to the outcome of the EU referendum.
Part of the work of the medicines and medical device regulator involves looking at existing research to help reach conclusions about potential and emerging issues with devices.
MHRA has produced draft guidance for medical devices including drug-device combination products and we welcome your comments
The Medicines and Healthcare products Regulatory Agency (MHRA) is investigating an issue involving a digital calculator used by some GPs to assess the potential risk of heart disease in patients.
The MHRA-led WEB-RADR project held its General Assembly in London on April 21
MHRA issue letter to the editor of the Sunday Post in response to ‘Deadly toll of dodgy NHS gear. Thousands killed or seriously injured by faulty equipment’ article.
The WHO has declared Zika a "public health emergency of international concern." MHRA is part of the global coalition responding to the outbreak.
The Agency is holding a second public session of its board meeting. Register now to attend the meeting in April.
MHRA are making improvements to the change of ownership application (COA) process for medicines marketing authorisations (MA).
New rules approved by the European Parliament will require safety features on the packaging of medicines at risk of falsification
4 May 2016: Conference on accelerated development and access to innovative medicines for patients.
MHRA has launched a campaign highlighting the work of pharmaceutical assessors and the role they play in protecting public health.
MHRA investigators seize more than 28,000 unlicensed slimming pills in Manchester area.
Scientists at the National Institute for Biological Standards and Control (NIBSC) dispel some of the common myths about flu vaccines.
The agency will pilot holding board meetings in public in 2016.
2 March 2016: joint MHRA and ABPI training event
CPRD is planning to redevelop its website and is looking for feedback on how the current website is used.
These modules are now available online through the National Association of Medical Device Educators and Trainers (NAMDET).
8 February 2016: conference for medical device safety officers (MDSO) and medication safety officers (MSO) to explore key themes in patient safety.
Looking back at what the Medicines and Healthcare products Regulatory Agency has achieved over the last year.
Payment details for MHRA bank account will change from 18 January.
Patients with advanced melanoma are among the first in the world to access pembrolizumab through the early access to medicines scheme (EAMS).
23 February 2016: registration now open for hot topics seminar covering key topics on advertising and promotion.
1 to 5 February 2016: This 5-day course will cover European clinical pre and post-Marketing safety regulatory requirements.
Ministerial Departmental News
- PM's Office, 10 Downing Street
- Cabinet Office
- Department for Business, Innovation and Skills
- Department for Communities and Local Government
- Department for Culture, Media and Sport
- Department for Education
- Department for Environment, Food and Rural Affairs
- Department for International Development
- Department for Transport
- Department for Work and Pensions
- Department of Energy and Climate Change
- Department of Health
- Foreign and Commonwealth Office
- HM Treasury
- Home Office
- Ministry of Defence
- Ministry of Justice
- Northern Ireland Office
- Scotland Office
- Wales Office
- See all departments